25 results about "Low insulin" patented technology

The invention discloses application of oxidized berberine and berberrubine in treatment of diabetic osteoporosis, and belongs to the technical field of biological medicine. Researches find that both oxidized berberine and berberrubine have the effect of treating diabetic osteoporosis, and can significantly improve the femur microstructure of a diabetic osteoporosis model animal, so that the femur microstructure recovers to a normal level; the blood glucose clearing capacity can be improved, the insulin resistance index is reduced, and the insulin signal channel function is recovered; the oxidative stress state of diabetic osteoporosis model animals can be relieved, the proinflammatory factor level is reduced, and the anti-inflammatory and anti-oxidation effects are achieved. The invention provides a new scheme and data support for the treatment of diabetic osteoporosis, has better curative effect, safety and economy than the prior art, and has important clinical transformation value.

The invention relates to a small-dose automatic metering, subpackaging and storing device and a control method thereof, and relates to the technical field of medical medication configuration and intravenous infusion dosing assistance. The intelligent metering injection unit is arranged in the shell and is used for fixedly mounting a disposable syringe; the piston displacement detection assembly is used for detecting piston displacement in real time; the piston driving and locking mechanism is used for driving the piston of the disposable syringe to automatically shift and be locked at a target dose position; the main control module is used for calculating the actual dose according to the piston displacement; wherein the intelligent metering injection unit provides axial guidance for the disposable syringe, the main control module controls the piston driving and locking mechanism according to the actual dose calculated by the piston displacement detection assembly, and closed-loop metering is achieved. High-precision control over insulin small-dose intravenous dosing can be achieved, the pollution risk caused by pumpback or repeated puncture is avoided, and the actual use loss of insulin injection is reduced on the whole.

The invention discloses an application of TAS2R14 in regulation and control of ADAMTS1 (adenosine monophosphate-adenosine monophosphate) in treatment of insulin resistance. Specifically, the invention provides application of TAS2R14 protein, mRNA or an expression vector thereof, the TAS2R14 protein, the mRNA or the expression vector thereof are used for preparing a preparation or a composition, and the preparation or the composition is used for (a) relieving oxidative stress; (b) reducing insulin resistance (IR). The preparation or composition of the invention effectively reduces insulin resistance and oxidative stress.

The invention is applicable to the technical field of biological medicines, provides application of ophiopogon japonicus borneol glycoside in preparation of a medicine for preventing and treating gestational metabolic diseases, and aims to solve the technical problems that the conventional medicine is limited in use during pregnancy, and the curative effect and the safety are difficult to take into account. According to verification of multi-model systems such as animals, cells and human-derived trophoblast organs, it is found that ophiopogon japonicus borneol glycoside can significantly improve gestational glycometabolism disorder, improve insulin sensitivity and reduce insulin resistance, and therefore effective intervention on gestational diabetes mellitus is achieved. As a natural component derived from the Zhejiang radix ophiopogonis, the radix ophiopogonis borneol glycoside has definite pharmacological activity and excellent safety, and the Zhejiang radix ophiopogonis is listed in a national homology of medicine and food, so that reliable safety guarantee is provided for use during pregnancy.

This invention belongs to the field of biomedical technology and discloses the application of NP in the preparation of a glycemic regulator for aging type 2 diabetes. The NP is a nanoscale complex formed by hydrogen bonding of turtle egg peptide with a molecular weight less than 3 kDa and naringenin at a mass ratio of 100:1. The formulation promotes liver glycogen synthesis and repairs pancreatic tissue structure and pancreatic β-cell function by activating the hepatic IRS1 / PI3K / AKT / GSK-3β signaling pathway and upregulating GLUT2 protein expression. The NP provided by this invention can significantly reduce fasting blood glucose levels in aging type 2 diabetic mice, improve oral glucose tolerance, and reduce the area under the blood glucose curve. Simultaneously, by restoring insulin signal transduction, it significantly reduces the insulin resistance index and improves the insulin sensitivity index, with an improvement level approaching that of the classic hypoglycemic drug metformin.

The present invention relates to modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and / or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and / or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors.

The invention relates to a nutritional composition. The nutritional composition consists of fucosyllactose, neutral non-fucosyllactose and sialic acid lactose. According to the nutritional composition disclosed by the invention, by additionally supplementing the nutritional composition in daily diet, the insulin sensitivity is further improved and / or the insulin resistance is reduced, so that a synergistic effect is achieved, and the blood glucose homeostasis of pregnant women is improved.

The present disclosure relates to a composition containing parsnip extract as an active ingredient which reduces the downregulation of tight junction protein expression, promote the proliferation of beneficial intestinal bacteria, improve the intestinal environment such as maintaining a slightly acidic intestinal environment, and have effects such as reducing intestinal permeability. Therefore, the composition may improve intestinal health and prevent, treat, or improve leaky gut syndrome, and may be used as a material for foods, feeds, pharmaceuticals, or quasi-drugs. Additionally, the composition may have body fat reduction and weight loss activities, reduce the protein expression of lipid metabolism-related factors such as ACC, FAS, SREBP1, ChREBP, G6PD, or C / EBPα, and have effects such as reducing liver weight, reducing blood sugar, reducing ALT or AST levels, reducing insulin resistance, and reducing extent of liver damage. Therefore, the composition may prevent, treat, or improve obesity or a metabolic disease.

The invention belongs to the technical field of biological medicines, and particularly relates to application of EPA (eicosapentaenoic acid) plasmalogen in preparation of medicines for improving or preventing diabetic nephropathy, which is characterized by treating diabetic nephropathy mouse models induced by high fat diet and streptozotocin and having insulin resistance and hyperglycemia accompanied by kidney lipid accumulation and glomerular filtration rate reduction, and particularly relates to application of EPA plasmalogen in preparation of medicines for improving or preventing diabetic nephropathy. The treatment effect of the EPA plasmalogen on the diabetic nephropathy is observed; results show that the EPA plasmalogen has obvious effects of improving kidney functions and kidney ectopic lipid deposition on diabetic nephropathy mice induced by high fat diet and streptozotocin, and also has the effects of reducing blood sugar, improving blood fat, reducing insulin resistance and the like. The EPA plasmalogen is used for intervening the diabetic nephropathy for the first time, and an important basis is provided for clinically treating the diabetic nephropathy by using the EPA plasmalogen.

The present invention relates to a composition effective in treating diabetes and dyslipidemia prepared according to the solid lipid nanotechnology from two natural phytochemical active ingredients: cinnamonaldehyde extracted from the Vietnamese cinnamon and berberine as a bioactive compound extracted from several plants, including a group of shrubs called Berberis. Via testing, all of the composition of the present invention has shown to have low toxicity and great bioavailability, reduced insulin resistance that allows the sugar level in blood to more effectively induce reduction of insulin, hyperglycolysis that aids the body in cellular sugar decomposition, reduced sugar production in the liver, carbohydrate decomposition slowed down in the intestines, and an increasing in the number of beneficial microbes in the intestines. The composition is effective in reducing the total cholesterol level (TC), and non-HDL-cholesterol, and has a tendency to reduce TG level.

The application is a bifunctional cyclic peptide which reduces insulin and does not increase blood sugar but appropriately reduces blood sugar, and belongs to the technical field of biological medicine. 52‑69 The cyclic peptide is obtained by in-vitro modification and reformation on the basis of the original linear short peptide COX The application realizes the seemingly contradictory two aspects of functions, i.e. inhibiting insulin secretion while not increasing blood sugar, and even reducing blood sugar, and the mechanism may be that the sensitivity of the tissue to insulin is improved. We call it a bifunctional peptide. The bifunctional peptide can be used for congenital hyperinsulinemia, insulin resistance, high insulin of obese people, etc. Literature reports that the increase of insulin is the cause of obesity, but for a long time, we cannot reduce weight by reducing insulin because the blood sugar will increase after the reduction of insulin, and high blood sugar is more harmful to health. The cyclic peptide realizes the function of reducing insulin while the blood sugar does not increase, but is reduced, which opens up a new way for weight loss of obesity, and the peptide can be conveniently administered orally in addition to injection. The convenience of use is greatly improved.

A method allows people to not compromise on the taste and flavor of sugar-containing foods and beverages, while reducing the net effect of the sugar in the body. The method may include oral consumption of the enzyme alternansucrase to convert up to 90% of consumed sucrose and other carbohydrates into a carbohydrate complex of undigestible or slowly digestible α-1, 3 and α-1, 6 glucan fibers in the gastrointestinal tract. These glucan fibers have the properties of dietary fibers and a degree of polymerization ranging from 3 to greater than 100. The methods may aid in glucose control, reduce insulin resistance and support healthy glucose homeostasis in diabetic and pre-diabetic conditions. It may promote healthy gut bacteria and improve bowel movements to benefit overall digestive health. It may also be applied to obesity control by reducing blood glucose and, through the production of fiber, blood lipid levels, which supports cardiovascular health.

The application discloses a uORF element for regulating chicken insulin receptor expression and application thereof, belongs to the field of molecular biology and genetic engineering, and the nucleotide sequence of the uORF element is shown in any one of SEQ ID NO. 1-2; the application comprises any one of the following: (1) regulating the expression of firefly luciferase in eukaryotic cells; the eukaryotic cells are chicken embryo fibroblasts and chicken preadipocytes; (2) being applied to genetic breeding of chickens, and the genetic breeding is breeding of meat chickens with reduced insulin resistance; (3) application in preparation of a reagent for regulating the expression of chicken insulin receptors. The application can regulate the expression level of INSR, improve insulin sensitivity, and provide material support for research on the mechanism of insulin in regulating blood glucose.

The invention discloses an application of GPR110 as a therapeutic target of type 2 diabetes mellitus. The application discovers that the GPR110 gene is used as a therapeutic target of type 2 diabetes for the first time, and provides application of adenovirus-mediated GPR110 gene overexpression in preparation of drugs for treating type 2 diabetes. In an adult type 2 diabetes mouse model db / db, through caudal vein injection of adenovirus-mediated GPR110 overexpression, it is found that the type 2 diabetes related symptoms are significantly improved. The blood glucose level and the fasting blood glucose level are obviously reduced, and an insulin tolerance test (ITT) result shows that the insulin sensitivity is obviously improved. In addition, a decrease in serum insulin level prompts a reduction in pancreatic islet function burden. The results show that the adenovirus-mediated GPR110 overexpression can effectively improve the metabolic disorder of mice with type 2 diabetes mellitus, and a new intervention method and means are provided for the treatment of the type 2 diabetes mellitus.

This invention discloses a device for disinfecting insulin pumps, belonging to the field of insulin pump disinfection technology. It includes a disinfection chamber, a drive mechanism, a circulating motion mechanism, and a cleaning mechanism. The disinfection chamber has an inlet and an outlet on both sides. A feeding chute is located at the inlet on one side of the disinfection chamber, and a discharging chute is located at the outlet on the other side. This device can disinfect the entire surface of the insulin pump, and medical personnel can select the appropriate cleaning effect according to the required level of cleanliness, thus avoiding the limitation of only achieving the best cleaning effect and reducing the disinfection efficiency of the insulin pump during the disinfection process. Simultaneously, it can disinfect multiple insulin pumps at the same time and can also wipe away stains on the display screen and buttons on the surface of the insulin pump, further improving the cleaning and disinfection effect.

Described herein are methods of treating overweight, weight management, treating diabetes, reducing blood glucose, reducing insulin resistance, reducing serum triglyceride levels, and / or reducing adipose weight in a subject, the methods comprising administering an incretin mimetic and an inflammasome modulator to the subject. In some embodiments the method of treatment comprises administering an incretin mimetic and administering a compound of formulae (I), (II), (III), (IV), (V), (V-A), (V-B), (VI), (VII), or (0).

Provided herein are cultivated animal cells that are adapted to grow in growth medium that contains low-insulin or no exogenously provided insulin. Provided herein are cultivated animal cells that are adapted to grow in growth medium that contains low-transferrin or no exogenously provided transferrin. Provided herein are methods of cultivating animal cells in growth medium that contains low-insulin or no exogenously provided insulin. Provided herein are methods of cultivating animal cell in growth medium that contains low-transferrin or no exogenously provided transferrin. Also provided are food products made from cultivated animal cells.

This invention discloses a KDM4C inhibitor and its applications, relating to the field of biomedical technology. Specifically, this invention discloses the application of the KDM4C inhibitor in any of A1) to A5): A1) preparing a drug for the prevention or treatment of obesity; A2) preparing a drug for reducing weight; A3) preparing a drug for reducing food intake; A4) preparing a drug for reducing insulin sensitivity; A5) preparing a drug for enhancing glucose homeostasis. This is achieved through knockout... Kdm4c Inhibiting KDM4C gene activity or inhibiting KDM4C activity can significantly reduce obesity induced by a high-fat diet, thereby regulating the secretion of related hormones / adipokines, affecting food intake, improving insulin resistance, and enhancing insulin sensitivity, making it a potential target for the treatment of obesity.

This invention relates to the delivery of a composition, preferably a pharmaceutical composition, comprising D-pinitol, D-Chiro inositol or myo-inositol or any pharmaceutically acceptable salt thereof, for use in the treatment or prevention of disorders, diseases or conditions responsive to the stimulation of the ghrelin receptor in a subject in need thereof. In particular, for the treatment and / or prevention of disorders responsive to the positive modulation (stimulation) of the ghrelin receptor, such as diabetes, obesity-related disorders, and, most preferably, for treating or preventing age related conditions or diseases such as by promoting appetite, inhibiting insulin secretion and lowering insulin resistance, increasing growth hormone release, enhancing muscle vitality or fragility and treating or preventing sarcopenia by increasing net muscle mass, improving cognition (and / or treating or preventing diseases such as Azlheimer's disease, vascular dementia, Parkinson's Disease, and Huntington's disease) and treating or preventing age related hypertension.

The invention provides a composition with hypoglycemic activity and a preparation method and application thereof, and belongs to the technical field of biological medicine. According to the composition disclosed by the invention, cinnamon, turmeric and red ginseng which are homologous in medicine and food are used as core raw materials and are compounded with eggshell membrane extract; after scientific components in parts by weight, all the raw materials achieve synergistic interaction, the inhibition rate on alpha-glucosidase can be remarkably increased, hyperglycemia model rat tests prove that the composition can remarkably reduce the blood sugar concentration, zebra fish tests prove that the composition can remarkably reduce the insulin content and the glucose level, the blood sugar reducing effect is remarkable, and the composition is suitable for clinical application. The traditional Chinese medicine composition can be effectively applied to blood sugar reduction and diabetes treatment. The composition is simple in component, clear in composition, high in raw material safety and free of toxic and side effects, the risk of liver injury possibly caused by combination of multiple traditional Chinese medicines is effectively avoided, and the medication safety and patient compliance are greatly improved.

The invention discloses a tanlotide series composition with functions of improving pancreatic beta cell functions, regulating blood fat, repairing liver and kidney injury, resisting inflammation and resisting oxidation and application thereof, and belongs to the technical field of medicines. The composition is prepared from radix trichosanthis, radix puerariae, radix ophiopogonis, radix codonopsis, poria cocos, fructus mume, radix astragali seu hedysari preparata, radix glycyrrhizae, fructus schisandrae chinensis, radix rehmanniae, folium eriobotryae powder, epigallocatechin gallate, instant bean flour, corn oligopeptide powder, wheat oligopeptide powder and soybean peptide powder, and meanwhile, the composition further comprises synergistic components. The synergistic component is one or more of a ginseng extract, PQQ, a turmeric extract and black pepper powder, and the composition has the effect of improving the functions of pancreatic beta cells and can effectively reduce the insulin resistance index. The traditional Chinese medicine composition also has a remarkable effect of regulating blood fat, and meanwhile, can repair liver and kidney injuries caused by complications such as hyperglycemia and hyperlipidemia. In addition, it is found that the composition has good anti-inflammatory and anti-oxidation effects, inflammation caused by in-vivo tissue lesions can be effectively resisted, meanwhile, the content of glutathione peroxidase and superoxide dismutase in the body is increased, and tissue cell recovery is accelerated through the combined action of the glutathione peroxidase and the superoxide dismutase.

The present application relates to a kind of traditional Chinese medicine compositions, including the following weight parts of preparation raw materials: Huanglian 15~20 parts, Fashi 15~18 parts, Gualoupi 30~45 parts, Juhong 10~15 parts, Danshen 15~20 parts, Baishu 15~20 parts.The traditional Chinese medicine composition prepared in the present application has obvious effect of resisting non-alcoholic fatty liver disease (NAFLD), compared with Rosuvastatin, can further improve the lipid accumulation and balloon-like change of liver, improve the level of triglyceride (TG), cholesterol (TC), low-density lipoprotein (LDL-C) and high-density lipoprotein (HDL-C) in blood fat, reduce liver damage index glutamic-pyruvic transaminase (ALT), inhibit the expression of inflammatory factors (TNF-alpha and IL-1beta).At the same time, the body weight of NAFLD mouse can be significantly reduced, glucose tolerance can be improved, insulin sensitivity can be improved, insulin resistance can be reduced, and the efficacy of regulating intestinal flora and increasing the abundance of intestinal Akkermansia bacteria can be achieved.

The application discloses application of a 5'-monophosphate nucleotide composition in preparation of anti-aging and longevity drugs and / or functional foods, and belongs to the technical field of medicines.The composition is composed of 5'-monophosphate adenosine, 5'-monophosphate cytidine, 5'-guanylic acid disodium, 5'-uridylic acid disodium and hypoxanthine nucleotide, and the mass ratio of the acid types of CMP, AMP, UMP, GMP and IMP is respectively as follows: CMP: 15-78%, AMP: 6-44%, UMP: 7-40%, GMP: 7-51%, and IMP is 0 or greater than 0 and not higher than 2.5%. The composition can synergistically enhance various mechanisms such as significantly reducing an insulin resistance index, enhancing body anti-coagulation function, improving blood circulation, regulating metabolism of essential minerals such as lithium and copper and regulating intestinal flora ecology, delays aging and prolongs healthy life span. Animal experiment data show that, compared with a control group, the composition prolongs the median survival time of mice by 9.21-12.6%, and the equivalent human life span is 8.76-12.01 years. Human experiment data show that, compared with the control group, the composition intervention reduces the median age of DNA methylation by 3.08 years, and provides a new idea for developing anti-aging and longevity drugs and / or functional foods.